Most regional MA exits are not exits

Over the past two years, the trade press has assembled a running list of regional health plans said to be leaving Medicare Advantage: CDPHP, AvMed, Paramount, Blue Cross of Kansas City, UCare, Providence, and others. Read as a list, the announcements suggest a market in broad retreat. Whether those books of members actually ended, however, is a separate question, and answering it requires more than counting names in enrollment files.

Consider CDPHP. A scan of the Centers for Medicare and Medicaid Services (CMS) enrollment data by parent organization shows the Albany plan's MA book falling to zero in 2025, which certainly looks like an exit. Trace the underlying contracts, however, and the same book reappears under Lifetime Healthcare, the parent of Excellus BCBS, where it grew from roughly 57,500 members to more than 73,000. That is, the plan did not leave the market; ownership changed, and the members stayed. The distinction is only visible when enrollment is followed at the contract level, across re-attributions, rather than at the level of a parent's name.

When we ran that trace across a cohort of ten "exiting" plans, the list sorted into four rather different groups. Only four were true terminations, in which the book ends and members must find a successor: Blue Cross of Kansas City (2025), UCare (2026), AvMed's Florida book under Sentara (2026), and Providence (announced for 2027). Several were sales in which the book lived on; ProMedica sold Paramount to Medical Mutual of Ohio and enrollment grew under the new owner, much as CDPHP's did under Lifetime. Others were defensive affiliations, with independents such as Cambia, Highmark, Independent Health, and MVP combining for shared technology and capital while local brands kept operating. And one name did not belong on the list at all; the apparent 405,000-member collapse at Clear Spring was a standalone Part D book terminated under the 2025 redesign, while its small MA book actually grew.

The four true terminations share a pattern worth examining. Each plan was small relative to the market (Blue Cross of Kansas City peaked near 33,000 members), dependent on government lines without a commercial hedge (UCare's book had grown to 181,000 before insolvency ended it), or pruned by an acquirer managing a national portfolio. Providence is perhaps the most instructive case: its Oregon book was still growing, approaching 77,000 members, when leadership announced a wind-down and cited the efficiency advantages of national carriers. Growth, in other words, does not appear to overcome a scale floor; profitability at these sizes depends on technology and pharmacy economics that a sub-scale book cannot amortize.

It would be a mistake to read any of this as a story of failure. Most of these moves appear to be rational, often defensive decisions by mission-driven plans under genuine cost pressure. The practical implication sits elsewhere, with anyone underwriting or entering these markets: a parent-name enrollment scan will misprice them, counting exits that are actually consolidations and missing the quiet two-step in which a book is acquired first and trimmed later. The same owner-normalized, contract-level read applies wherever a book changes hands in public CMS data, and we treat what it surfaces as leads for diligence rather than conclusions.

A note on method, since this piece is as much about the read as the finding: everything above came from public CMS enrollment files, owner-normalized and traced at the contract level through Aequalis, our payer data platform, with deal records and audited financials layered on afterward. The work took an afternoon; the premise it corrected had been circulating for two years, which suggests how much of the received wisdom about these markets rests on reads nobody has traced.